Tuomas Tammela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9932604/publications.pdf

Version: 2024-02-01

61857 143772 12,851 59 43 57 citations h-index g-index papers 59 59 59 15787 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cellular and molecular mechanisms of plasticity in cancer. Trends in Cancer, 2022, 8, 735-746.	3.8	24
2	Expression of R-Spondin 1 in Apc Mice Suppresses Growth of Intestinal Adenomas by Altering Wnt and Transforming Growth Factor Beta Signaling. Gastroenterology, 2021, 160, 245-259.	0.6	21
3	WNT as a Driver and Dependency in Cancer. Cancer Discovery, 2021, 11, 2413-2429.	7.7	108
4	Investigating Tumor Heterogeneity in Mouse Models. Annual Review of Cancer Biology, 2020, 4, 99-119.	2.3	42
5	A MASCOT for mosaic analysis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30876-30878.	3.3	O
6	Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30670-30678.	3.3	11
7	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 2020, 38, 229-246.e13.	7.7	210
8	Exercise and immunometabolic regulation in cancer. Nature Metabolism, 2020, 2, 849-857.	5.1	25
9	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Science Translational Medicine, 2020, 12, .	5.8	58
10	Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. Nature, 2019, 571, 398-402.	13.7	166
11	Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2232-2236.	3.3	51
12	Colonoscopy-based colorectal cancer modeling in mice with CRISPR–Cas9 genome editing and organoid transplantation. Nature Protocols, 2018, 13, 217-234.	5.5	74
13	Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. Journal of Controlled Release, 2018, 290, 75-87.	4.8	35
14	A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature, 2017, 545, 355-359.	13.7	265
15	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology, 2017, 35, 569-576.	9.4	248
16	VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling. Circulation Research, 2017, 120, 1414-1425.	2.0	117
17	A Modular Assembly Platform for Rapid Generation of DNA Constructs. Scientific Reports, 2016, 6, 16836.	1.6	54
18	Growth factor therapy and lymph node graft forÂlymphedema. Journal of Surgical Research, 2015, 196, 200-207.	0.8	31

#	Article	IF	CITATIONS
19	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity, 2015, 43, 579-590.	6.6	360
20	The Schlemm's canal is a VEGF-C/VEGFR-3–responsive lymphatic-like vessel. Journal of Clinical Investigation, 2014, 124, 3975-3986.	3.9	179
21	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature, 2014, 516, 428-431.	13.7	353
22	Small RNA combination therapy for lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3553-61.	3.3	210
23	CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature, 2014, 514, 380-384.	13.7	673
24	Comparison of vascular growth factors in the murine brain reveals placenta growth factor as prime candidate for CNS revascularization. Blood, 2013, 122, 658-665.	0.6	30
25	Vascular Endothelial Growth Factor-Angiopoietin Chimera With Improved Properties for Therapeutic Angiogenesis. Circulation, 2013, 127, 424-434.	1.6	53
26	Ligand oligomerization state controls Tie2 receptor trafficking and Angiopoietin-2 ligand-specific responses. Journal of Cell Science, 2012, 125, 2212-23.	1.2	24
27	In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6223-6228.	3.3	108
28	Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis. Journal of the National Cancer Institute, 2012, 104, 461-475.	3.0	186
29	Essential Role of the Coxsackie - and Adenovirus Receptor (CAR) in Development of the Lymphatic System in Mice. PLoS ONE, 2012, 7, e37523.	1.1	41
30	Photodynamic Ablation of Lymphatic Vessels and Intralymphatic Cancer Cells Prevents Metastasis. Science Translational Medicine, 2011, 3, 69ra11.	5.8	103
31	VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nature Cell Biology, 2011, 13, 1202-1213.	4.6	272
32	Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema. Circulation, 2011, 123, 613-620.	1.6	163
33	Response to Letter Regarding Article, "Biological Basis of Therapeutic Lymphangiogenesis― Circulation, 2011, 124, .	1.6	0
34	Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis. Genes and Development, 2011, 25, 831-844.	2.7	145
35	Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood, 2011, 118, 1154-1162.	0.6	116
36	Biological Basis of Therapeutic Lymphangiogenesis. Circulation, 2011, 123, 1335-1351.	1.6	143

3

#	Article	IF	Citations
37	Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization. Cancer Cell, 2010, 18, 630-640.	7.7	119
38	Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation. Circulation, 2010, 122, 1725-1733.	1.6	129
39	Lymphangiogenesis: Molecular Mechanisms and Future Promise. Cell, 2010, 140, 460-476.	13.5	1,198
40	VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Current Opinion in Cell Biology, 2009, 21, 154-165.	2.6	636
41	Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C–dependent buffering mechanism. Nature Medicine, 2009, 15, 545-552.	15.2	835
42	Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature, 2008, 454, 656-660.	13.7	731
43	Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circulation Research, 2007, 100, 1468-1475.	2.0	34
44	Enhanced Capillary Formation Stimulated by a Chimeric Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor-C Silk Domain Fusion Protein. Circulation Research, 2007, 100, 1460-1467.	2.0	13
45	Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. Journal of Experimental Medicine, 2007, 204, 1431-1440.	4.2	167
46	Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nature Medicine, 2007, 13, 1458-1466.	15.2	321
47	Vascular Endothelial Growth Factor-C Accelerates Diabetic Wound Healing. American Journal of Pathology, 2006, 169, 1080-1087.	1.9	192
48	Yet another function for hepatocyte growth factor. Blood, 2006, 107, 3424-3425.	0.6	3
49	VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nature Neuroscience, 2006, 9, 340-348.	7.1	164
50	Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood, 2005, 105, 4642-4648.	0.6	218
51	Lymphangiogenesis in development and human disease. Nature, 2005, 438, 946-953.	13.7	1,117
52	Molecular lymphangiogenesis: new players. Trends in Cell Biology, 2005, 15, 434-441.	3.6	118
53	The biology of vascular endothelial growth factors. Cardiovascular Research, 2005, 65, 550-563.	1.8	680
54	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation, 2005, 115, 247-257.	3.9	475

Tuomas Tammela

#	Article	IF	CITATIONS
55	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation, 2005, 115, 247-257.	3.9	326
56	Vascular endothelial growth factor $\hat{a} \in \mathbb{C}$ gene therapy restores lymphatic flow across incision wounds. FASEB Journal, 2004, 18, 1707-1709.	0.2	89
57	Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends in Immunology, 2004, 25, 387-395.	2.9	351
58	Genesis and pathogenesis of lymphatic vessels. Cell and Tissue Research, 2003, 314, 69-84.	1.5	89
59	Lymphangiogenic Gene Therapy With Minimal Blood Vascular Side Effects. Journal of Experimental Medicine, 2002, 196, 719-730.	4.2	147